List view / Grid view
Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infections.
University of Warwick expertise is contributing to a world-first £1.5million study aiming to tackle one of the biggest public health threats we face - antibiotic resistance.
LifeArc, the UK medical research charity previously known as MRC Technology; The Centre for Drug Research and Development (CDRD); and the Defence Science and Technology Laboratory (Dstl), have announced a collaboration to identify antibacterial drug targets.
Scientists have given new superpowers to an antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections.
Researchers in dermatology at Lund University in Sweden believe they have cracked the mystery of why our bodies can quickly prevent an infection from spreading uncontrollably during wounding. They believe this knowledge may be significant in developing new ways to counteract bacteria.
New research provides insights into why infection with Zika virus after birth generally causes only mild symptoms, whereas devastating foetal malformations can develop when infection occurs during pregnancy.
Researchers develop bacteria-fighting wound dressing made with the help of crustaceans…
Pfizer has launched the Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries.
New findings could help to extend the lives of patients suffering from one of the most common types of brain tumours - low-grade glioma.
Polyphor Ltd, a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 million private placement. Exisiting Polyphor investors contributed to 98% of the financing.
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
This application note demonstrates the feasibility of combining the Thermo Scientific™ Varioskan™ LUX multimode reader and Invitrogen™ EVOS™ FL Cell Imaging System for the fluorescence-based quantification and imaging of complex biological systems, without requiring separate assay optimisation...
Polyphor has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates.
24 January 2017 | By
Author and Scientific Director Jean de Gunzburg, from Da Volterra, will present keynote speech at 19th annual Superbugs summit...
An team of scientists at the University of Nottingham has developed a technique to produce chemically functional spider silk that can be tailored to applications used in drug delivery, regenerative medicine and wound healing.
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Tuberculosis is the most deadly infectious disease in the world. Standard TB therapy takes at least 6 months and patients infected with multi-drug...
